Velagliflozin proline_product_DataBase

Bioactivity	Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations[1].
In Vivo	Velagliflozin (1 mg/kg, 口服, 单剂量) proline 增加胆固醇、白蛋白、β -羟基丁酸 (BHB)、非酯化脂肪酸 (NEFA) 和尿葡萄糖排泄，并降低猫的呼吸交换比率[1]。 Velagliflozin (0.3 mg/kg; 口服; 每天 1 次, 共 18 天) proline 耐受性良好，可通过降低饮食非结构性碳水化合物 (NSC) 的高胰岛素反应来处理小马的胰岛素失调和预防椎板炎[2]。
Name	Velagliflozin proline
CAS	1539295-26-5
Formula	C28H34N2O7
Molar Mass	510.58
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Hoenig M, et al. Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats. J Vet Pharmacol Ther. 2018 Apr;41(2):266-273. [2]. Meier A, et al. The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies. PLoS One. 2018 Sep 13;13(9):e0203655.

PeptideDB